OraTech will leverage HTIT's manufacturing capabilities and focus on developing and commercializing innovative products globally based on ORMP's technology & pipeline. HTIT is a high-tech company focused on biopharmaceutical product manufacturing and R&D with an emphasis on the oral delivery of therapeutic macromolecules. It operates an oral insulin manufacturing facility in China. Separately, with ORMP's strong balance sheet - ~$142m in cash, equivalents, ST investments & deposits at YE24 - capital allocations include share buybacks, a potential cash dividend and strategic investments in early stage companies designed to boost total returns to shareholders.
